Stay updated on Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial
Sign up to get notified when there's something new on the Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial page.

Latest updates to the Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedMajor update: version bumped to v3.2.0 with an important government-operating-status notice and a new term (Epidermolysis bullosa dystrophica); old version v3.1.0 removed. If this page is disease-related, the new term may affect terminology or search indexing.SummaryDifference4%

- Check32 days agoChange DetectedThe page has been updated to version v3.1.0 and several related topics (MedlinePlus topics on drug safety, counterfeit drugs, pharmaceutical preparations, and substandard drugs) have been removed.SummaryDifference0.6%

- Check47 days agoChange DetectedThe page version was updated from v3.0.1 to v3.0.2, and the 'Back to Top' link/button was removed.SummaryDifference0.2%

- Check54 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%

- Check61 days agoChange DetectedThe web page has been updated to include new facility and drug information, specifically regarding Beremagene Geperpavec, while removing outdated location details and certain genetic disease resources.SummaryDifference9%

- Check75 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial page.